Browse HP

Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00089 Trypsin
Function

As a result of hemolysis, hemoglobin is found to accumulate in the kidney and is secreted in the urine. Haptoglobin captures, and combines with free plasma hemoglobin to allow hepatic recycling of heme iron and to prevent kidney damage. Haptoglobin also acts as an Antimicrobial; Antioxidant, has antibacterial activity and plays a role in modulating many aspects of the acute phase response. Hemoglobin/haptoglobin complexes are rapidely cleared by the macrophage CD163 scavenger receptor expressed on the surface of liver Kupfer cells through an endocytic lysosomal degradation pathway. ; FUNCTION: Uncleaved haptoglogin, also known as zonulin, plays a role in intestinal permeability, allowing intercellular tight junction disassembly, and controlling the equilibrium between tolerance and immunity to non-self antigens.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0002526 acute inflammatory response
GO:0006898 receptor-mediated endocytosis
GO:0006953 acute-phase response
GO:0006979 response to oxidative stress
GO:0009636 response to toxic substance
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010035 response to inorganic substance
GO:0010310 regulation of hydrogen peroxide metabolic process
GO:0010727 negative regulation of hydrogen peroxide metabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0042542 response to hydrogen peroxide
GO:0042742 defense response to bacterium
GO:0042743 hydrogen peroxide metabolic process
GO:0042744 hydrogen peroxide catabolic process
GO:0051341 regulation of oxidoreductase activity
GO:0051354 negative regulation of oxidoreductase activity
GO:0072593 reactive oxygen species metabolic process
GO:0098542 defense response to other organism
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1990748 cellular detoxification
GO:2000295 regulation of hydrogen peroxide catabolic process
GO:2000296 negative regulation of hydrogen peroxide catabolic process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
Molecular Function GO:0016209 antioxidant activity
GO:0030492 hemoglobin binding
Cellular Component GO:0030139 endocytic vesicle
GO:0031838 haptoglobin-hemoglobin complex
GO:0031983 vesicle lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0071682 endocytic vesicle lumen
GO:0072562 blood microparticle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-2168880: Scavenging of heme from plasma
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8910.476
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9770.642
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.2890.158
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3060.308
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2550.849
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3710.822
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8060.464
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2350.433
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2290.894
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0420.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2130.961
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.2510.0123
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHP
Namehaptoglobin
Aliases BP2ALPHA2; HPA1S; binding peptide; haptoglobin alpha(1S)-beta; haptoglobin alpha(2FS)-beta; haptoglobin, alp ......
Chromosomal Location16q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.